Reno- and Vascular Protective Effect of a Vitamin-D-analogue in Moderate to Severe Chronic Kidney Disease
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
Recently it has been documented that vitamin D has important functions in the human body that
are unrelated to its primary effects in calcium homeostasis and bone mineralization. In
clinical studies, paricalcitol - a low-calcemic vitamin D analogue - has been shown to
decrease proteinuria, a marker of disease progression and cardiovascular risk in patients
with chronic kidney disease (CKD). The purpose of this study is to investigate the effect of
a paricalcitol on renal and cardiovascular variables in patients with moderate to severe CKD.